Pancreatic cancer remains a highly malignant disease with a nearly identical estimated annual incidence and mortality rate in 2008 (1) . Gemcitabine is still being regarded as the standard chemotherapeutic agent for the treatment of locally advanced and metastatic disease (2) . The value of adding a second drug to single-agent gemcitabine remains controversial: a statistically significant (but clinically moderate) survival benefit was only observed with the combination regimen of gemcitabine plus erlotinib to date (3, 4) . Despite the need for improving therapeutic options in pancreatic cancer, innovative approaches for personalized medicine will also be required in this aggressive disease, e.g., by establishing clinically relevant prognostic and predictive biomarkers.
The carbohydrate antigen 19-9 (CA 19-9) has been studied widely in pancreatic cancer as a serum tumor marker for diagnostic, prognostic, and predictive significance. CA 19-9 was first described in 1979 by Koprowski and colleagues (5, 6) as a tumor-associated antigen defined by a monoclonal antibody (1116 NS that was produced by a hybridoma prepared from mouse spleen immunized with a human colorectal carcinoma cell line. CA 19-9 is also the sialysiated Lewis (Le) a blood group antigen, and individuals lacking the Lewis-antigen glycosyltranferase (Le a−b− phenotype) are unable to synthesize CA 19-9 (7). Especially with regard to the difficulties in evaluating treatment response by standard imaging in pancreatic cancer (e.g., due to the desmoplastic stroma reaction with local inflammation and fibrosis), a serum biomarker could serve as a useful surrogate tool in determining treatment efficacy noninvasively and quickly in this disease (8) .
Several previous studies suggested a significant correlation between a biochemical CA 19-9 response and survival end points in patients receiving systemic chemotherapy for pancreatic cancer (8) (9) (10) (11) (12) (13) (14) ; however, a subgroup analysis of a large prospective phase III trial could not confirm such a significant prognostic role of CA 19-9 kinetics in patients with advanced pancreatic cancer (15) . One main limitation of some previous studies derives from the fact that the investigators did not apply a standardized assay for the measurement of CA 19-9, and thus, an unknown assaydependent bias may be included in their results (8) . Furthermore, the statistical methods and definitions for evaluating a biochemical CA 19-9 response were not unique and standardized among many of these trials.
The aims of this retrospective multicenter study were as follows: first, to evaluate the prognostic role of baseline CA 19-9 in patients with advanced pancreatic cancer, and to determine CA 19-9 levels during front-line chemotherapy in a homogenous group of pancreatic cancer patients with the use of one defined CA 19-9 assay. Second, to apply statistical models that analyze pretreatment CA 19-9 and CA 19-9 kinetics as a continuous variable and not as categorized variable, which is a widely used but criticizable approach (16) . Third, to establish univariate and multivariate Cox models in which changes of CA 19-9 during chemotherapy could be included as a time-varying covariate.
Patients and Methods
Patient population and treatment. Male or female patients with a histologically or cytologically confirmed diagnosis of locally advanced or metastatic exocrine pancreatic cancer were considered eligible for the current retrospective study. Patients with previous chemotherapy or radiotherapy for advanced disease were ineligible, and all included patients received front-line treatment for advanced pancreatic cancer (systemic chemotherapy or chemoradiotherapy). Consecutive patients meeting the above eligibility criteria were recruited from the "Pancreas Center" at the Department of Internal Medicine III, Ludwig-Maximilans-University of Munich, and additionally selected patients treated within a prospective multicenter phase II trial (evaluating the combination of gemcitabine/oxaliplatin with the monoclonal antibody cetuximab; GEMOXCET trial) were also included (17) . Patients treated outside clinical trials received standard gemcitabine or gemcitabine-based chemotherapy or chemoradiotherapy until disease progression, unacceptable toxicity, or patient refusal. Routine radiological tumor assessment and response evaluation was done by computed tomography or magnetic resonance imaging according to the standard Response Evaluation Criteria in Solid Tumors every 6 to 9 wk.
CA 19-9 measurement. For each patient, CA 19-9 was measured locally but with the use of a defined ELISA assay (Elecsys, Roche Diagnostics) at all participating centers. Each patient from the GEMOXCET phase II trial that was monitored with the Elecsys assay was included in the current analysis. The upper limit of the reference range for CA 19-9 was defined-according to the manufacturer's instructions-with 37 U/mL. To exclude patients with undetectable CA 19-9 from this analysis (Lewis blood group antigen typing was not done routinely), a pretreatment CA 19-9 level of >5.2 U/mL (according to > 2 × detection limit for CA 19-9) was requested for each included patient. Baseline CA 19-9 was measured before the start of first-line therapy and about each 4 to 6 wk thereafter. For the analysis of CA 19-9 kinetics, at least three measurements during chemotherapy had to be available. CA 19-9 determinations were collected prospectively in each patient.
Study design and statistical analyses. This was a retrospective, multicenter study conducted in five German oncological centers. The predefined end point of this study was to show a correlation of baseline CA 19-9 and CA 19-9 kinetics during first-line therapy with time-to-progression (TTP) and overall survival (OS). TTP was defined as the interval between the initiation of treatment and the occurrence of disease progression under first-line treatment or thereafter, but before an eventual second-line therapy; OS was defined as the time interval between the initiation of treatment and death from any cause. The analyses of CA 19-9 kinetics were done only in a homogeneous group of patients receiving systemic chemotherapy (patients treated with chemoradiotherapy for locally advanced disease were excluded from the kinetic analysis, but were suitable for baseline analysis).
The pretreatment CA 19-9 level was treated as a continuous variable that was transformed by taking the logarithm [log(CA ]. The effect of pretreatment log(CA 19-9) on TTP and OS was modeled by Cox proportional hazards regression. The effect of the serially measured CA 19-9 values (CA 19-9 kinetics) was also modeled by using the Cox model where CA 19-9 was transformed again by taking the logarithm [log(CA ] and where log(CA 19-9) was treated as a time-varying covariate with a constant value between two measurements. It should be
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noted that the log(CA 19-9) is modeled as a step function with jumps at the measurement points (18) . The statistical formulae for estimating such incidence curves could be described as follows: x i describes the baseline covariates of patient i. μ i (t) describes the one-dimensional marker measurement of patient i at time t. The longitudinal marker information is derived through an imputation rule for all time points based on a few discrete measurements. The regression coefficients of the Cox-regression for the baseline covariates are given by the vector β, and the coefficient for the effect of the biomarker is quantified by γ. Therefore, the instantaneous hazard rate at time point s during the observation interval for patient i is formally quantified by
The cumulative hazard for patient i is given by ¦ Ã½t x i ; f i ðsÞ; s½0; tg ¼ This novel approach allowed us to model the effect of the most recent measured value of log(CA 19-9) during therapy on the event (TTP or OS) instead of modeling the effect of the pretreatment value of log(CA 19-9) on TTP and OS, respectively. In addition, it should be pointed out that models with time-varying covariates are no longer proportional hazards models because the cumulative hazard cannot be separated anymore in a factor derived from the (time varying) baseline hazard and a factor derived from (time varying) covariates (19) . We calculated the univariate Cox models for modeling the effect of pretreatment log(CA 19-9) and log(CA 19-9) kinetics, and univariate models of other known prognostic factors [including gender, age, Karnofsky performance status (KPS), stage of disease (locally advanced versus metastatic stage), and treatment (e.g., mono versus combination therapy)] on TTP and OS using each with complete cases with regard to these prognostic factors. We furthermore developed multivariate Cox models for modeling the effect of pretreatment log(CA 19-9) and log(CA 19-9) kinetics on TTP and OS where we, on one hand, selected some potentially prognostic factors by using backward elimination performing likelihood ratio tests on a significance level of 0.05 (two sided) and, on the other hand, by calculating multivariate models taking all aforementioned potentially prognostic factors into account again using complete cases. We checked the assumptions of the Cox regression models by using graphically based residual analyses where we evaluated the proportional hazards assumption (which is only possible for the two Cox models with the pretreatment CA 19-9), the functional form of the continuous covariates [using penalized spline-based techniques for the Cox models with time-varying log(CA 19-9), among others], and possible influential observations. For all analyses, STATA (version 10) and R (version 2.9.0) was used, and a P value of 0.05 or lower was considered as statistically significant. The estimation of TTP and OS for the whole study population was done using the Kaplan-Meier method.
Results

Patient characteristics
Overall, 115 patients from five German centers were included in this study. Patients were treated between (Continued on the next column) therapy. The median pretreatment CA 19-9 level in the study population was 1,059 U/mL, and ranged between 9.5 and 100,000 U/mL. Median pretreatment serum bilirubin level was 0.6 mg/dl (range, 0.2-5.3).
Baseline CA 19-9
For CA 19-9 baseline analyses, all treatment-naive patients with advanced pancreatic cancer (locally advanced or metastatic) receiving front-line therapy (chemoradiotherapy or chemotherapy only) were eligible.
Time-to-progression. Detailed results from the Cox model evaluating the linear effect of pretreatment log(CA 19-9) on TTP are summarized in Table 2 . In the univariate analysis, log(CA 19-9) was significantly associated with TTP [hazard ratio (HR), 1.24; P < 0.001]. When developing multivariate Cox regression models, we had 112 complete cases where 82 (73%) patients developed progression during first-line therapy or-where applicable-in the time after first-line therapy and before the start of secondline therapy. With the use of backward elimination, no other potentially prognostic factor than log(CA 19-9) was selected. The effect of log(CA 19-9) on TTP lowered but remained statistically significant in the multivariate model with all potentially prognostic factors included (HR, 1.19; P = 0.003). Residual analyses showed adequate fit for the full and reduced multivariate Cox models especially with regard to the proportional hazards assumption and linearity assumptions.
Overall survival. The pretreatment CA 19-9 level was identified as a prognostic factor for OS in univariate and multivariate analyses, respectively. As shown in Table 2 , the linear effect of log(CA 19-9) shows a HR of 1.16 (P = 0.002) in the univariate Cox regression model. In the multivariate analyses, we had 113 complete cases where 89 patients (79%) died. The multivariate Cox model that was developed by using backward elimination yields a HR of 1.16 (P = 0.004) for death adjusted for KPS at treatment initiation. In the multivariate model including all potentially prognostic factors, the HR for the effect of log(CA 19-9) was estimated with 1.13 (P = 0.016). Residual analyses showed adequate fit of both multivariate Cox models especially with regard to the proportional hazards assumption and linearity assumptions.
CA 19-9 kinetics
For CA 19-9 kinetic analyses, only patients receiving front-line chemotherapy (no chemoradiotherapy) were eligible. Furthermore, at least three CA 19-9 measurements during first-line chemotherapy had to be available.
Time-to-progression. The HR for log(CA 19-9) at any given time was 1.48 (P < 0.001) in the univariate Cox model (Table 3) . For 67 patients, complete data were available for multivariate Cox regression analyses of the effect of log(CA 19-9) kinetics on TTP during first-line chemotherapy. Of these 67 patients, 52 (78%) had a documented tumor progression. The HR for log(CA 19-9) adjusted for age as developed by backward elimination is slightly lowered (HR, 1.45) and remains statistically significant (P < 0.001). When adjusting for all prognostically relevant factors, the HR was 1.55 (P < 0.001). A statistical interpretation of the two adjusted HRs of log(CA 19-9) could be as follows: given the same values of the other included factors for two patients, the HR of 1.45 (1.55) is the hazard of progression at time t for the patient with a log(CA 19-9) value before time t, relative to the hazard of progression at time t for the patient whose log(CA 19-9) before time t is decreased by exactly one unit (18) . The residual analyses for both multivariate Cox models showed no influential observations, and the penalized spline-based methods suggested the logarithmic transformation of CA 19-9 as an adequate one.
When using Cox models with time-varying covariates, we specify, besides the prognostically important factors and the pretreatment value of log(CA 19-9), an entire covariate path of the serially measured log(CA 19-9) values for a single patient. Figure 1 graphically illustrates the individual risk calculation for three exemplary study patients regarding the end point "probability of progress under first-line therapy" during chemotherapy by including CA 19-9 as a time-varying covariate in the Cox model. For each time point, a patient-specific risk assessment for TTP ("incidence curve"; Fig. 1A ) may be estimated based on log(CA 19-9) kinetics (Fig. 1B) . The steepness of the incidence curve for TTP in Fig. 1A ("backward elimination" model) thereby is determined by the kinetics of log(CA 19-9) (Fig. 1B) . In Fig. 2 , all study patients that were available for the analysis "TTP and log(CA 19-9) kinetics" (n = 67) are included (each line represents the incidence curve for one single study patient). We additionally grouped the incidence curves for these 67 patients with regard to their pretreatment CA 19-9 levels [tercile 1: baseline CA 19-9, <309 U/mL (Fig. 2A) ; tercile 2: baseline CA, 19-9, 309-3,543 U/mL (Fig. 2B) ; tercile 3: baseline CA 19-9, >3,543 U/mL; (Fig. 2C)] . Each incidence curve illustrates the estimated individual event probabilities for each patient with regard to progression using his/her own covariate path of log(CA 19-9) and his/her values of prognostically important factors up to the last observation time. Solid lines indicate that the end point "progression under first-line therapy" has occurred in this patient; dashed lines indicate that the progression has not (yet) occurred.
Overall survival. Data from 84 patients were analyzed for a correlation of CA 19-9 kinetics during chemotherapy and OS (Table 3) . Log(CA 19-9) as a time-varying covariate was significantly associated with OS in univariate analysis (HR, 1.34; P < 0.001). When performing multivariate analyses, we had complete data on 82 patients of whom 64 (78%) had died. Multivariate analyses yielded a HR of 1.38 (P < 0.001) in the case of the backward elimination (adjusted for performance status, sex, and treatment with combination therapy versus single-agent therapy). Residual analyses again showed no influential observations, and the penalized spline-based methods suggested the logarithmic transformation of CA 19-9 as an adequate one.
Discussion
Previous investigators reported inconsistent results for the prognostic role of CA 19-9 kinetics as surrogate end point for treatment efficacy in advanced pancreatic cancer (8) . However, there is evidence that pretreatment CA 19-9 levels before the start of up front chemotherapy can be regarded as a prognostic factor for OS (8, 15, 20) , an observation that is also confirmed by data reported here. Hess et al. (15) recently published their CA 19-9 biomarker analysis, which was a secondary end point in a randomized phase III trial conducted to determine the role of adding capecitabine to standard gemcitabine in advanced pancreatic cancer. Of the 319 randomized study patients, 175 (55%) were evaluable for CA 19-9 tumor marker response analyses. Using a landmark method, no significant correlation was found either between an early CA 19-9 decline (defined as a >50% CA 19-9 reduction after two cycles of treatment) nor between a CA 19-9 decrease of >50% at the CA 19-9 nadir during first-line chemotherapy and OS. This study did not apply a unique CA 19-9 assay for a (central) tumor marker assessment. In contrast, an Italian group recently performed a pooled analysis including 204 patients from five consecutive prospective clinical pancreatic cancer trials and found a significant correlation between a predefined CA 19-9 nadir variation and OS in univariate and multivariate analyses (20) .
Our retrospective multicenter study met its predefined end point: CA 19-9 baseline levels as well as CA 19-9 kinetics (using a time-varying covariate Cox model) during front-line therapy for advanced pancreatic cancer were both found to be significant prognostic factors for OS and also for TTP in univariate and multivariate analyses (Tables 2 and 3 ). It should be noted that the multivariate HRs for TTP when using log(CA 19-9) as a time-varying covariate became larger (1.45 and 1.55) compared with the HRs where pretreatment log(CA 19-9) were used (1.24 and 1.19). The same yields for the multivariate HRs for OS (1.38 and 1.37 versus 1.16 and 1.13). One might conclude that continuous CA 19-9 monitoring possibly allows a more precise determination of its prognostic biological significance, compared with the use of the pretreatment value of CA 19-9 only (see Figs. 1 and 2) . The clinical interpretation of the statistical results obtained Fig. 1 . Incidence curve for TTP (A) in three exemplary study patients using a multivariate Cox model with backward elimination technique: based on individual serial log(CA 19-9) kinetics during first-line chemotherapy (B), a patient-specific risk assessment for TTP may be estimated for each time point (A). Fig. 2 . Incidence curves for all 67 study patients analyzed for a correlation of log(CA 19-9) kinetics and TTP, additionally grouped with regard to pretreatment CA 19-9 categories; A, tercile 1: baseline CA 19-9, <309 U/mL; B, tercile 2: baseline CA 19-9, 309-3,543 U/mL; C, tercile 3: baseline CA 19-9, >3,543 U/mL. Each line represents the incidence curve for one single study patient. Solid lines, end point progression under first-line therapy has occurred; dashed lines, end point progression under first-line therapy has not (yet) occurred.
from this study could be-for example-as follows: the linear effect of pretreatment log(CA 19-9) on TTP was determined with a HR of 1.24 (P < 0.001) in an univariate Cox model (Table 2) ; if a theoretical patient 1 has a baseline CA 19-9 that is one log higher than the baseline CA 19-9 of patient 2, patient 1 has a 24% increase in the risk of disease progression. Additionally, the time-varying covariate model allows the determination of a specific, individual risk assessment for disease progression at a defined time point during first-line therapy based on incidence curves (as shown in Fig. 1A ). These incidence curves are calculated on the basis of a multivariate Cox model (using backward elimination strategy) in which serial measurements of log(CA 19-9) during chemotherapy are included as a time-varying covariate (Fig. 1B) .
Of note, all CA 19-9 measurements in this study were conducted with the use of one defined assay (Elecsys), thus ruling out an assay-dependent analytic bias (8, 21) . In addition, we did not categorize CA 19-9, but modeled CA 19-9 as a continuous covariate where we found the logarithmic transformation of CA 19-9 as an adequate one to model the nonlinear relationship between CA 19-9 and the corresponding hazard. Categorization may lead to loss of information and can increase the rate of false-positive findings when using more than two categories of CA 19-9 (16) .
The main limitations of this investigation arise from its retrospective nature (of note: >70% of included patients were treated within prospective clinical pancreatic cancer trials and CA 19-9 values were measured prospectively in each patient) and the limited number of patients included. However, as the main aim of this study was to establish a new statistical model for serially measured CA 19-9 values per patient in pancreatic cancer, our results should be regarded as hypothesis-generating, and we strongly recommend validating this approach within the setting of a prospective clinical trial in an independent patient cohort. This multicenter study aimed to address a scientific-academic approach to determine the robustness of the serum marker CA 19-9 in pancreatic cancer, and the authors are aware of the fact that the direct clinical applicability of results generated with this novel analytic model may be limited. However, in the light of the absence of a clear and internationally accepted scientific rationale for the routine use of CA 19-9 monitoring in advanced pancreatic cancer, our study may in fact provide a further step for establishing this biomarker as a useful tool in pancreatic cancer.
Emerging data recently that became available confirm the prognostic (and even subsequent therapeutic) significance of CA 19-9 monitoring in the perioperative setting in pancreatic cancer (22) (23) (24) (25) ; however, in patients with advanced disease, only a limited number of phase III trials reported CA 19-9 data to date (8, 15) . The evaluation of new molecular prognostic and predictive markers is urgently awaited in pancreatic cancer, but investigators should also continue to focus on validating the currently available biomarkers (e.g., CA 19-9) with the use of innovative statistical methods and within appropriately designed prospective clinical trials. Based on actual innovative data from other disease entities (26) (27) (28) , a biomarker-driven, or tumor markerdriven, trial design could also be applied in pancreatic cancer (e.g., in the adjuvant setting or for stratification purposes in advanced disease).
In conclusion, this retrospective multicenter study adds evidence for an important prognostic role (about TTP and OS) of both pretreatment CA 19-9 and CA 19-9 kinetics in patients with advanced pancreatic cancer. Based on the data generated here, a profound CA 19-9 evaluation (including Lewis antigen typing and prospective validation of new statistical models) is scheduled for a planned prospective clinical trial of the Pancreatic Cancer Group of the "Arbeitsgemeinschaft Internistische Onkologie" of the German Cancer Society.
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